Goldstein S A, Van Vunakis H
J Pharmacol Exp Ther. 1981 Apr;217(1):36-43.
Antibodies have been produced in rabbits immunized with a fluphenazine succinate-human serum albumin conjugate. By radioimmunoassay it is possible to quantify fluphenazine (FPZ), related phenothiazine drugs and several of their metabolites at the femtomole level. As little as 370 fmol (160 pg) of FPZ can be detected and up to 0.4 ml of plasma can be added to the incubation mixture (final volume = 1.1 ml). The phenothiazine heterocyclic nucleus is immunodominant and determines the specificity of the antiserum. When a parent drug cross-reacts significantly with antibody, its 7-hydroxide, N-oxide and N-10 side chain altered metabolites can also be determined by the assay. The 8-hydroxide, sulfoxide and 7-hydroxyglucuronide metabolites are not detectable unless present in large amounts. High-performance liquid chromatography was used to separate phenothiazine drugs and metabolites. Since the antiserum has broad specificity, a combined high-performance liquid chromatography and radioimmunoassay procedure permits the identification and quantification of a phenothiazine drug and its serologically reactive metabolites. Patterns of high-performance liquid chromatographic elution and extent of immunologic cross-reaction are characteristic for metabolites relative to the parent drug. This procedure offers distinct advantages in the analysis of this complex family of compounds. FPZ was quantitatively extracted from plasma samples obtained from patients receiving FPZ per os. Although large amounts of serological activity were present in the samples 2 to 6 hr after FPZ ingestion, only 2 to 23% was extractable. The major contributors to the serological activity at times greater than 6 hr were FPZ metabolites. In a preliminary application of the combined techniques, FPZ and a metabolite identified as N-[alpha-(trifluoromethylphenothiazinyl-10)propyl]perazine were quantified in the organic extract of one plasma sample.
用氟奋乃静琥珀酸酯 - 人血清白蛋白偶联物免疫家兔产生了抗体。通过放射免疫测定法能够在飞摩尔水平上对氟奋乃静(FPZ)、相关的吩噻嗪类药物及其几种代谢物进行定量。低至370飞摩尔(160皮克)的FPZ即可被检测到,且孵育混合物中可加入多达0.4毫升血浆(最终体积 = 1.1毫升)。吩噻嗪杂环核具有免疫显性,决定了抗血清的特异性。当母体药物与抗体有显著交叉反应时,其7 - 羟基、N - 氧化物和N - 10侧链改变的代谢物也可通过该测定法进行测定。除非大量存在,否则8 - 羟基、亚砜和7 - 羟基葡萄糖醛酸代谢物无法检测到。采用高效液相色谱法分离吩噻嗪类药物和代谢物。由于抗血清具有广泛的特异性,高效液相色谱法与放射免疫测定法相结合的程序可用于鉴定和定量吩噻嗪类药物及其血清学反应性代谢物。相对于母体药物,代谢物的高效液相色谱洗脱模式和免疫交叉反应程度具有特征性。该程序在分析这一复杂化合物家族时具有明显优势。从口服FPZ的患者获得的血浆样本中定量提取了FPZ。尽管在摄入FPZ后2至6小时的样本中存在大量血清学活性,但只有2%至23%是可提取出来的。在超过6小时时,血清学活性的主要贡献者是FPZ代谢物。在该联合技术的初步应用中,对一个血浆样本的有机提取物中的FPZ和一种被鉴定为N - [α - (三氟甲基吩噻嗪基 - 10)丙基]哌嗪的代谢物进行了定量。